APA (7th ed.) Citation

Cao, J., Teng, Y., Li, H., Zhang, L., Ouyang, Q., Xie, W., . . . Hu, X. (2023). Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): A single-arm, multicenter phase 2 trial. BMC Medicine, 21(1), 1. https://doi.org/10.1186/s12916-023-02999-0

Chicago Style (17th ed.) Citation

Cao, Jun, et al. "Pyrotinib Plus Capecitabine for Trastuzumab-resistant, HER2-positive Advanced Breast Cancer (PICTURE): A Single-arm, Multicenter Phase 2 Trial." BMC Medicine 21, no. 1 (2023): 1. https://doi.org/10.1186/s12916-023-02999-0.

MLA (9th ed.) Citation

Cao, Jun, et al. "Pyrotinib Plus Capecitabine for Trastuzumab-resistant, HER2-positive Advanced Breast Cancer (PICTURE): A Single-arm, Multicenter Phase 2 Trial." BMC Medicine, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12916-023-02999-0.